Basil Polysaccharide Reverses Development of Experimental Model of Sepsis-Induced Secondary Staphylococcus aureus Pneumonia

Figure 1

(a) Experimental procedure. We randomized mice into 6 groups, including 4 receiving CLP at D0 and 2 receiving sham operation. At 3 days later (D3) or at D0 in the sham operation group, mice were given intratracheal injection with P. aeruginosa (PA,  CFU) or S. aureus (SA,  CFU). Two hours after the bacterial hit or the second bacterial hit, basil polysaccharide or IgG was injected intraperitoneally as an intervention. We collected lung tissues, blood, and BALF at 24 h after a bacterial infection or secondary bacterial infection for analysis. In the 10-day experimental period, we recorded the mortality rates of all groups to analyze the survival. (b) The mortality rates were monitored for 10 days after the challenge with S. aureus ( mice/group). (c, d) Lung or blood bacterial CFU in each group after administration with S. aureus ( mice/group). (e–g) Lung injury assessment indicators such as protein in BALF, myeloperoxidase, and wet/dry weight ratio in the lung were measured after challenge with S. aureus ( mice/group). Log-rank (Mantel-Cox) test was performed to analyze survival curves. Values were presented in the manner of , while one-way ANOVA as well as LSD multiple comparisons test was adopted for data analysis. ^#, compared with S. aureus infection treated with basil polysaccharide. ^▲, compared with CLP-surgery mice upon secondary S. aureus infection treated with basil polysaccharide. , , and , upon one-way ANOVA as well as LSD multiple comparisons. Compared with S. aureus infection treated with basil polysaccharide group or CLP-surgery mice upon secondary S. aureus infection treated with the basil polysaccharide group.

(a)

(b)

(c)

(d)

(e)

(f)

(g)